NCT06101277View on ClinicalTrials.gov

Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)

NARecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

October 5, 2023

Primary Completion Date

December 5, 2025

Study Completion Date

January 5, 2031

Conditions
Esophageal CancerSmall Bowel CancerGastroesophageal-junction CancerGastric CancerColorectal CancerAppendiceal CancerBiliary CancerGall Bladder CancerIntrahepatic CholangiocarcinomaExtrahepatic CholangiocarcinomaOligoprogressive
Interventions
DEVICE

Ablative local therapy

Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy

Trial Locations (1)

95817

RECRUITING

University of California, Davis, Sacramento

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of California, Davis

OTHER